Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$546.66+2.34%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Madrigal is growing sales of Rezdiffra, from $287M to $311M. Losses are smaller, improving from -$114M to -$94M. The company is building partnerships to help growth. These steps show progress toward financial health.
Madrigal still loses money and may not reach profit soon. Sales growth might slow or stop. Partnerships may not bring enough new business. Costs could stay high and hurt results.
The price is near our fair value of about $544. Analysts expect 57% revenue growth. Our fair value is below the Street median by 11%. We see risk in profit and growth timing.
Breaks if: Net loss worsens below -$114 million next year
Manage operating expenses and cash to reduce net losses and maintain a strong cash position for ongoing operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
MDGL represents a speculative growth investment with a focus on expanding its product offerings. The current thesis state is stable, supported by strong growth in its Rezdiffra product line, although it faces elevated risks in the near term.
The market currently reflects a justified valuation, with expectations slightly below what is considered aligned with peers. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Fundamentals are likely to show continued growth in Rezdiffra sales, which have already demonstrated significant year-over-year increases. However, the company's elevated risk profile and mixed progress on its pipeline could introduce volatility.
The thesis hinges on management's ability to maintain growth momentum for Rezdiffra and successfully advance its MASH pipeline. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'moderate'.
Yes, our read has strengthened. The latest earnings beat supports the thesis. Rezdiffra's growth aligns with management's objectives and drives robust growth. There are no new threats impacting the outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Net loss improved from $94.4 million in 2026-Q1 to $57.9 million in 2026-Q2. Cash, cash equivalents, restricted cash and marketable securities increased from $817.9 million to $838.9 million over the same period. The trajectory shows progress toward financial stability as management emphasized.
“Net loss was $57.9 million; cash and equivalents of $838.9 million as of June 30, 2026”
“Net loss was $94.4 million; cash and equivalents of $817.9 million as of March 31, 2026”
Breaks if: Rezdiffra revenue falls below $287 million next year
Maximize long-term value and sales growth of Rezdiffra, the foundational MASH therapy, through expanding patient adoption and market penetration.
Stated as a priority in 2 of last 2 quarters. Rezdiffra net sales grew from $137.3 million in 2025-Q1 to $311.3 million in 2026-Q1 (+127%), and further to $364.3 million in 2026-Q2 (+71% year-over-year). Patient count more than doubled from 2Q25 to over 49,000 in 2Q26. The trajectory is delivering robust growth as management emphasized.
“Second-quarter 2026 Rezdiffra net sales of $364.3 million, representing year-over-year growth of 71%”
“First-quarter 2026 Rezdiffra net sales of $311.3 million, representing year-over-year growth of 127%”
Breaks if: No new partnerships formed or partnerships fail to grow
Overall, MDGL's position is supported by solid product growth and a stable management team, but it faces risks that could impact its trajectory. Not investment advice.